Horizon Europe: Health

Development of new effective therapies for rare diseases

Deadline: 1 februari 2022

Less than 6% of rare diseases have an approved treatment option. By approaching rare diseases with commonalities like shared biological features proposals should address multiple rare diseases and not a single disease.

Proposals for this call should contribute to at least one of the following outcomes:

  • Researchers make better use of new knowledge
  • Researchers use robust preclinical technologies to increase the successful development of new therapies for rare diseases.
  • Regulators can approve therapies for rare diseases faster due to more successful late-stage interventions tested.
  • People living with rare disease get access to new therapies or medical products

Call ID: HORIZON-HLTH-2022-DISEASE-06-04-two-stage

Financiert projecten binnen:

De officiële aanmelding van Horizon Europe: Health

Contact betreffende subsidie van Horizon Europe: Health

Past deze aanmelding bij uw project? We nemen graag contact met u op voor een vrijblijvend advies over de Horizon Europe: Health subsidiemogelijkheden voor uw project.

Alle aanmeldingen van Horizon Europe: Health

Over Horizon Europe: Health

The Horizon Europe: Health Cluster supports research and innovation that contribute to Europe’s recovery and resilience from the global pandemic as well as projects aimed at the cancer care pathway. There are six specific areas of impact contained in the Health Cluster:

  • Staying healthy in a rapidly changing society
  • Living and working in a health-promoting environment
  • Tackling diseases and reducing disease burden
  • Ensuring access to innovative, sustainable and high-quality health care
  • Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
  • Maintaining an innovative, sustainable and globally competitive health-related industry
Meer over de subsidies